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Abstract
Background Activation of proteinase-activated recep-
tor-4 (PAR-4) from the colonic lumen has an antino-
ciceptive effect to colorectal distension (CRD) in mice
in basal conditions. We aimed to determine the
functional localization of the responsible receptors
and to test their role in two different hyperalgesia
models. Methods Mice received PAR-4 activating
peptide (PAR-4-AP, AYPGKF-NH2) or vehicle intra-
peritoneally (IP), and abdominal EMG response to
CRD was measured. The next group received PAR-4-
AP intracolonically (IC) with or without 2,4,6-triami-
nopyrimidine, a chemical tight junction blocker,
before CRD. The SCID mice were used to test the role
of lymphocytes in the antihyperalgesic effect. The
effects of PAR-4-AP and PAR-4-antagonist (P4pal-10)
were evaluated in water avoidance stress (WAS)
model and low grade 2,4,6-trinitrobenzene sulfonic
acid (TNBS) colitis. Spinal Fos protein expression was
visualizedby immunohistochemistry.KeyResults The
antinociceptive effect of PAR-4-AP disappeared when
was administrered IP, or with the blockade of colonic
epithelial tight junctions, suggesting that PAR-4-AP
needs to reach directly the nerve terminals in the colon.
The CRD-induced spinal Fos overexpression was
reduced by 43% by PAR-4-AP. The PAR-4-AP was an-
tihyperalgesic in both hyperalgesia models and inmice
with impaired lymphocytes. The PAR-4-antagonist
significantly increased the TNBS, but not the WAS-in-
duced colonic hyperalgesia. Conclusions & Infer-
ences The antinociceptive effect of PAR-4-AP depends
on its penetration to the colonic mucosa. The PAR-4
activation is endogenously involved as a feedback loop
to attenuate inflammatory colonic hyperalgesia to
CRD.
Keywords proteinase-activated receptor, TNBS,
visceral pain.
Abbreviations: Cat-G cathepsin G; CRD colorectal dis-
tension; DRG dorsal root ganglion; IBS-D diarrhea-
predominant irritable bowel syndrome; IC intracolonically;
IP intraperitoneally; MPO myeloperoxidase; P4pal-10
N-palmitoyl-SGRRYGHALR-NH2; PAR-4 proteinase-
activated receptor-4; PAR-4-AP PAR-activating peptide;
SC subcutaneous; SCID severe combined immunodeﬁ-
ciency; TAP 2,4,6-triaminopyrimidine; TNBS 2,4,6-trini-
trobenzene sulfonic acid; WAS water avoidance stress.
INTRODUCTION
Proteinase-activated receptors (PARs), a family of
7-transmembrane G-protein-coupled receptors are
activated by the cleavage of their N-terminal domain
by serine-proteases, which unmasks a new amino
terminal sequence activating the receptor itself.1 The
PARs other than PAR-3 can be cleaved by synthetic
peptides, called PAR-activating peptides (PAR-APs),
with sequences based on their tethered ligand. The
molecule AYPGKF-NH2 is a PAR-4-AP, which has no
effect on either PAR-1 or PAR-2,1 and whose effects are
blocked by a PAR-4 antagonist.2
The PARs play an important role in gastrointes-
tinal physiology and pathophysiology 3 and are
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involved in the sensation of visceral pain. The PAR-2
activation induces colorectal hypersensitivity to
distension in rats,4 and its activation by high level
of serine-proteases is likely to contribute to the
pathogenesis of diarrhea-predominant irritable bowel
syndrome (IBS-D). Indeed fecal supernatants from
IBS-D patients induce colorectal hypersensitivity to
distension in mice via PAR-2 activation.5 Unexpect-
edly, fecal supernatants from ulcerative colitis
patients, containing similar elevated level of serine-
proteases as IBS-D patients decrease colorectal
sensitivity in the same model through a predominant
activation of PAR-4, overriding PAR-2 activation.6
Further, cathepsin-G (Cat-G), a PAR-4 activator
contained in neutrophil granulocytes is highly pres-
ent in this fecal supernatant, and was identified as
promoting such colonic hyposensitivity.6 Despite its
direct proinflammatory properties in the gut
associated with increased colonic permeability,7
luminal activation of colonic PAR-4 by its agonist
peptide PAR-4-AP produces similar visceral analgesia
to colorectal distension (CRD) in mice.6 The PAR-4-
AP has been detected on the colonic epithelium,8 but
also in dorsal root ganglion (DRG) neurons9 or
immunocytes.10 Therefore, the localization of the
receptors participating in the antinociceptive effect is
not clear. Hence, we have first tested if intraperito-
neal (IP) administration of PAR-4-AP is able to
mimic the hyposensitivity seen after intracolonic
(IC) infusion. Despite the presence of PAR-4 on
apical site of colonocytes, due to its small size
(<15 kDa) PAR-4-AP may be absorbed through tight
junctions to reach mucosal nerve terminals. Conse-
quently, we evaluated if the blockade of colonic
epithelial tight junctions may change the effect of
PAR-4-AP IC infusion. As a next step, to test if
colonic lymphocytes are involved in the mechanism
we used SCID mice which bear with functionally
defective T and B cells due to a mutation in the
Prkdc gene.11 In our previous study, the activation of
colonic PAR-4 was analgesic in mice in basal
conditions,6 nevertheless, in colitis, fecal Cat-G
may be in contact with inflamed mucosa, where
hyperalgesic neuromodulators are highly present. To
evaluate a possible antihyperalgesic effect, PAR-4
agonist and Cat-G were also tested in inflammatory
(2,4,6-trinitrobenzene sulfonic acid, TNBS) and non-
inflammatory (water avoidance stress, WAS) models
of colorectal hypersensitivity to distension. In
addition, the use of a selective antagonist in these
conditions may allow us to detect a possible
physiologic analgesic role of PAR-4, in such
conditions.
MATERIALS AND METHODS
Animals
The 8–9 week-old (21–23 g) C57BL/6J wild-type male mice, BALB/
cBy Prkdcscid (SCID) mice and their BALB/cBy controls (Janvier,
Le Genest St-Isle, France) were used in our study. The animals
were kept in polypropylene cages in a temperature-controlled
roomwith a 12-h dark–light cycle, water and standard pellets were
provided ad libitum. All experimental procedures were approved
by both the local Institutional and the Midi Pyrene´es Animal Care
and Use Committees.
Visceral pain measurement
Under anesthesia (xylasine + ketamine, both 1.2 mg SC in
0.07 mL in 0.9% NaCl) two nickel-chrome electrodes (diameter:
0.08 mm) were implanted in the abdominal external oblique
muscle and the third in the abdominal skin as described previ-
ously.6 On the 4–7th postoperative days, colorectal distensions
were performed as painful stimuli to evoke abdominal electro-
myographic response as a sign of visceral sensitivity. The animals
were placed in a plastic tunnel, and after 1 h of habituation period,
mice were lightly anaesthetized by sodium pentobarbital (1 mg in
0.15 mL 0.9% NaCl, IP), and polyethylene perfusion and disten-
sion catheters (Fogarty catheter for artherial embolectomy, 4F,
balloon length: 1.1 cm, Edwards Lifesciences, Nijmegen, The
Netherlands) were inserted into the colon (the tip of the catheters
situated at 3.5 and 2.5 cm from the anus, respectively).5,6 Colo-
rectal infusions were started when mice recovered completely
from anesthesia (e.g. in <60 min). The CRD procedure was
performed with volumes progressively increasing in 0.02 mL
steps from 0 to 0.10 mL, by injecting physiologic saline to the
balloon with a Hamilton syringe (500 lL, Hamilton Company,
Bonaduz, Switzerland), each step lasting 10 s with 5 min non-
distension periods in-between. During the distension periods, the
abdominal muscle electrical activity was recorded and analyzed
with Powerlab Chart 5 program from AD instruments. Basal EMG
activity was subtracted from the EMG activity registered during
the periods of distension.
Elucidation of mechanism of action
Effect of IC vs IP PAR-4 activating peptide on colorectal
sensitivity Mice received PAR-4-AP (AYPGKF-NH2, Sigma,
St Quentin Fallavier, France; 100 lg in 0.15 mL 0.9% NaCl) or its
vehicle in IP bolus injection or in IC infusion. Visceral sensitivity
measurements started 1 h following the end of IC infusion and
15 min after the IP administration.
Effect of the tight junction blocker TAP on PAR-4 activation-
induced hyposensitivity Mice received 2,4,6-triaminopyrimidine
(TAP, Sigma; total dose: 30 lmol per mouse in 0.1 + 0.15 mL
0.9% NaCl) IC 1 h preceding PAR-4-AP IC infusion (as previously
described), followed by a parallel administration of IC TAP. Vis-
ceral sensitivity measurements started 1 h following the end of
infusion.
SCID mice Male SCID mice and their BALB/cBy controls were
operated as C57BL/6J mice, and on the 4th postoperative day mice
received IC infusion of 100 lg PAR-4-AP or vehicle as described
above. Visceral pain measurements started 1 h following the end
of infusion.
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Visceral hypersensitivity models
Water avoidance stress model Modification of a previously
described protocol has been used.12 Briefly, C57BL/6J mice were
placed on a 3 · 3 cm platform in a 40 · 40 cm size pool filled with
tapwater for 1 h on four consecutive days. The animals who fell
into the water were gently dried with a towel and placed back to
the platform.
Colonic microinflammation Low-grade colonic inflammation
was provoked by IC administration (tip of the catheter 3.5 cm
from the anus) of a low dose of TNBS (Sigma, 20 mg kg)1 mice) in
40 lL 30% ethanol or 0.9% NaCl in C57BL/6J mice on the 4th
postoperative day, as described earlier.13 Visceral sensitivity
measurements were performed 72 h after the administration of
TNBS. To assess the low-grade colonic inflammation level,
myeloperoxydase activity assays were performed.
Myeloperoxidase activity assay Myeloperoxidase (MPO) activity,
a marker of polymorphonuclear neutrophil granules, was assessed
in colonic tissues according to previously described techniques
(Bradley et al., 1982) and measured to provide an index of
neutrophil infiltration and intestinal inflammation. Protein
concentration was assessed using BCA protein assay kit (Inter-
chim, Montlucon, France) and MPO activity was expressed as
units per g of protein.
Treatments One group of WAS and TNBS mice received IC
infusion of 100 lg PAR-4-AP or its vehicle and visceral sensitiv-
ity was measured 1 h after the end of infusion. Next group of
WAS- and TNBS-treated animals were IC infused by 0.025 UN of
Cat-G (Sigma, 0.167 UN mL)1 in 0.15 mL 0.9% NaCl) or its
vehicle and CRD was performed similarly 1 h after the end of
infusion. Another group was treated with 0.75 mg kg)1 PAR-4
antagonist (P4pal-10, pepducin, NeoMPS, Strasbourg, France;
N-palmitoyl-SGRRYGHALR-NH2 in 0.15 mL 0.9% NaCl) or its
vehicle IP, and the response to CRD was tested 30 min after the
injection.
Cat-G activity in the feces Following the fourth water avoidance
session in the WAS model or 72 h after the administration of
TNBS in the colitis model, fecal samples of mice were collected
for Cat-G activity measurement, and fecal supernatants were
prepared (0.3 g feces in 4 mL 20 mmol L)1 Tris HCl, pH: 8.3). Cat-
G activity in the fecal supernatant was measured by an enzymatic
assay as described previously using N-succinyl-Ala-Ala-Pro-Phe
p-Nitroanilide (Sigma).6
Fos immunohistochemistry
Mice received IC PAR-4-AP infusion (100 lg in 0.15 mL 0.9%
NaCl) or its vehicle, 0.9% NaCl and 1 h later underwent the CRD
protocol as described above. A group of mice without treatment
and distension served as naive controls. One hour after the
completion of the CRD, mice were deeply anesthetized with
xylazine-ketamine (both 2 mg IP) and perfused transcardially with
50 mL physiologic saline followed by 50 mL of 4% paraformalde-
hyde. After fixation, lumbosacral segments (L5-S1) of the spinal
cord were dissected and removed, postfixed at +4 C in 4%
buffered paraformaldehyde, incubated in 30% sucrose (24 h,
+4 C), embedded (Tissue Tek medium) and frozen in isopentane
at )45 C. Frozen serial sections (35 lm) were collected in
phosphate-buffered saline (PBS), then rinsed twice. Sections were
stained for Fos-like immunoreactivity using biotin-avidin-
peroxidase complex. Briefly, sections were incubated at room
temperature in a blocking solution for 30 min and then incubated
with rabbit polyclonal Fos antibody diluted in blocking solution
(1 : 10 000; Ab-5, AbCys, Paris). The incubated sections were
washed twice and incubated with biotinylated goat anti-rabbit
secondary antibody, diluted 1 : 1000 in blocking solution, and
then incubated with the avidin-biotin complex (Vectastain Elite
kit; Vector Laboratories, Paris, France). Peroxidase activity was
revealed using diaminobenzidine as chromogene (DAB substrate
kit, Vector Laboratories, France). The presence of Fos immunore-
activity was detected as a dark brown reaction product in cell
nuclei under a light microscope (90i Nikon, Nikon France,
Champigny-sur-Marne, France). The number of cells containing
Fos immunoreactivity was counted in the laminae I-II and the
area surrounding the central canal (area X) bilaterally in 16
consecutive sections of the lumbosacral segment of the spinal
cord (L5-S1), using Lucia G4.8 software.
Statistical analysis
Results are presented as means ± SEM. Data analysis was
performed by using Graphpad Prism software (Graph Pad, La
Jolla, CA, USA). For the statistical analysis of MPO results,
Student t-test was used to compare the two groups (control vs
TNBS). Data obtained in fecal Cat-G activity and Fos immuno-
histochemistry measurements were compared by analysis of
variance, followed by Tukey post hoc test. In the visceral pain
experiments, means were calculated for each volume from all
values in a group receiving the same treatment, and data were
compared by analysis of variance, followed by Tukey post hoc
test.
RESULTS
Comparative influence of IC vs IP administration
of PAR-4-AP on colorectal sensitivity to
distension
When infused intracolonically prior to distension,
PAR-4-AP (100 lg) triggered a hyposensitivity to CRD
at the distension volumes from 0.04 to 0.08 mL
compared with vehicle infusion (P < 0.05). In contrast,
when injected intraperitoneally at the same dose,
PAR-4-AP had no effect on the response to CRD
(P > 0.05) compared with vehicle. Indeed, abdominal
response to CRD after PAR-4-AP administration was
significantly different between IC and IP routes at the
same distension volumes (P < 0.05; Fig. 1A).
Effects of TAP on PAR-4-AP evoked
hyposensitivity
The colorectal infusion of TAP blocked the hyposen-
sitive effect of PAR-4-AP IC infusion (Fig. 1B). The
PAR-4-AP alone decreased the sensitivity by 54–33%
at distension volumes of 0.04–0.08 mL, respectively
(P < 0.05). On the contrary, PAR-4-AP + TAP did not
affect the sensitivity compared with vehicle (P > 0.05).
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The TAP alone had no effect on colorectal sensitivity
(P > 0.05).
SCID mice
Postoperative complications and mortality was not
different in SCID mice compared with their Balb/cBy
controls. Compared with their BALB/cBy controls,
SCID mice had a significantly greater abdominal
response to CRD at the distension levels of 0.04 to
0.1 mL increasing the intensity of EMG response by
384% to 132%, respectively (P < 0.01; P < 0.01;
P < 0.01; P < 0.001). PAR-4 activation effectively re-
versed this hypersensitivity (P < 0.01, P < 0.05;
P < 0.05; P < 0.05; Fig. 1C).
Influence of PAR-4-AP and PAR-4 antagonist
on WAS-induced colorectal hypersensitivity
Water avoidance stress significantly increased visceral
sensitivity to distension by 730%, 119%, and 69%, at
distension volumes of 0.02, 0.04, and 0.06 mL, respec-
tively (P < 0.01, P < 0.05, P < 0.05, Fig. 2A). Intraco-
lonic infusion of PAR-4-AP before distension
suppressed the colonic hypersensitivity to distension
and restored it to the baseline at all distension
volumes. Further, the PAR-4 antagonist had no impact
on the visceral hypersensitive response to CRD
observed in stressed mice (Fig. 2B).
Influence of PAR-4-AP and PAR-4 antagonist
on TNBS-induced colorectal hypersensitivity
Seventy-two hours after intracolonic infusion of TNBS,
the abdominal response to CRD was enhanced by
1529%, 98%, and 90% at distension volumes of 0.02,
0.04, and 0.06 mL, respectively, when compared with
controls without TNBS (P < 0.001, P < 0.05, P < 0.01,
Fig. 3A). Intracolonic infusion of PAR-4-AP, prior to
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Figure 1 Effect of PAR-4-AP on visceral sensitivity by IP administra-
tion, in combination with tight junction blockade or in SCID mice.
Electromyographic activity of abdominal muscle contractions evoked
by CRD in mice after IP injection or IC infusion of 100 lg PAR-4-AP or
its vehicle, 0.9% saline. Each line represents themean EMG response of
all animals tested in the same group. (A) PAR-4-AP was antinociceptive
by IC (n = 12, *P < 0.05), but not by IP (n = 9, P > 0.05) route at the
distension levels from0.04 to 0.08 mLcomparedwith saline (n = 8). The
abdominal EMG response was significantly different between IC and IP
routes at these distension volumes (§P < 0.05). (B) The blockade of tight
junctions by TAP abolished the antinociceptive effect of intracolonic
PAR-4-AP (PAR-4-AP, n = 9, vs PAR-4-AP + TAP, n = 12; §P < 0.05;
whereas PAR-4-AP vs saline, n = 8, *P < 0.05). The TAP alone had no
effect on colorectal sensitivity (TAP, n = 8 vs saline, P > 0.05). (C) SCID
mice (n = 7) were significantly hypersensitive to CRD compared with
their BalbC/cBy controls (n = 8; **P < 0.01, ***P < 0.001), which was
reversed by PAR-4 activation (n = 8; #P < 0.05; ##P < 0.01).
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distension suppressed the increased sensitivity to CRD
for all volumes. Unexpectedly, treatment with the
PAR-4 antagonist increased the TNBS-induced hyper-
sensitivity by 78%, 42%, and 19% at distension
volumes of 0.04, 0.06, and 0.08 mL compared with
TNBS alone (P < 0.05, P < 0.05, P < 0.05; Fig. 3B).
Influence of Cat-G on WAS and TNBS-induced
colorectal hypersensitivity
The intracolonic infusion of Cat-G significantly
decreased the hypersensitivity observed in WAS-trea-
ted mice at volumes from 0.02 to 0.08 mL (P < 0.05;
P < 0.05; P < 0.01, P < 0.01; Fig. 4A). Surprisingly, Cat-
G could not reverse the visceral hypersensitivity
induced by low-grade TNBS inflammation (saline vs
TNBS + Cat-G; P < 0.05 at the distension volumes of
0.04 and 0.06 mL and P < 0.01 at the volume of
0.08 mL; Fig. 4B).
Cathepsin-G activity in feces of mice after WAS
and TNBS treatment
Cat-G activity was significantly increased in feces of
mice with TNBS colitis (17.0 ± 2.6 U mg)1 prot) com-
pared with naı¨ve controls (8.8 ± 1.9 U mg)1 prot). In
contrast, Cat-G activity was not elevated in the feces of
stressed mice compared with naı¨ve controls
(6.9 ± 2.5 U mg)1 prot, P > 0.05; Fig. 3C).
Evaluation of colonic inflammation induced by
a low dose of TNBS
Three days after intracolonic instillation, a low dose of
TNBS (20 mg kg)1) induces a slight, but a significant
increase of MPO in TNBS mice compared with control
(12.7 ± 2.1 vs 8.34 ± 1.2, respectively; Fig. 3D). This
slight elevated MPO activity was also associated to a
slight mucosal thickening in TNBS mice compared
with control and to a slight body weight loss 3 days
after intracolonic TNBS instillation (Table 1).
Effects of PAR-4-AP on the CRD-induced spinal
Fos expression
In naı¨ve mice, the number of Fos-positive cells in the
L5-S1 levels of the spinal cord was 7.4 ± 0.7 per
section. This number was markedly increased (4.9-
fold) after CRD in the group treated with saline
compared with naı¨ve, undistended animals (P < 0.001;
Fig. 5A, B). However, pretreatment with PAR-4-AP IC
infusion reduced the CRD-induced Fos expression
increase by 46% in the spinal cord compared with
saline (P < 0.001; Fig. 5A, B).
DISCUSSION
In addition to our previous data showing the antinoci-
ceptive effect of intracolonic PAR-4-AP6 confirmed by
others,14 this work demonstrates that this effect is
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Figure 2 Effect of PAR-4 activation and blockade in water avoidance
stress model. Electromyographic activity of abdominal muscle con-
tractions evoked by CRD in mice either 1 h after colorectal infusion of
100 lg PAR-4-AP or its vehicle, or 30 min after PAR-4 antagonist IP
injection in water avoidance stress. Each line represents the mean
EMG response of all animals tested in the same group. (A) Water
avoidance stress increased sensitivity to CRD shown by the elevation
in the EMG activity (WAS, n = 11 vs saline, n = 10, *P < 0.05,
**P < 0.01), which was abolished by PAR-4-AP infusion (WAS vs
WAS + PAR-4-AP; n = 12, #P < 0.05, ##P < 0.01). (B) PAR-4 antagonist
(n = 10) did not change the visceral hypersensitivity provoked by water
avoidance stress (saline vs WAS, *P < 0.05).
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driven locally. Further, we provide new information on
the presence of an endogenous activation of PAR-4 in
inflammatory mediated hypersensitivity acting as a
feed-back mechanism controlling pain, not activated in
stress-induced visceral hyperalgesia.
The localization of PAR-4 responsible for the
antinociceptive effect
PAR-4 is present in the colonic epithelium,8 but also in
dorsal root ganglion (DRG) neurons, where its activa-
tion does not induce a calcium signal, but reduces the
calcium signal evoked by KCl.9 The involvement of
PAR-4 in nociception has been shown in rat knee joint
primary afferents as well.15 Further, patch clamp
recordings show that PAR-4 activation in DRG neu-
rons projecting to the colon suppresses their excitabil-
ity.16 PARs are also found on the surface of different
immune cells throughout the gastrointestinal tract,
where their activation may trigger the release of
various chemokines and growth factors,10 interfering
with nociceptive pathways. Our present findings on
the failure of systemic PAR-4-AP administration to
reduce visceral pain sensation is in accordance with
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Figure 3 Effect of PAR-4 activation and blockade in TNBS-induced hypersensitivity. Electromyographic activity of abdominal muscle contrac-
tions evoked by CRD in mice either 1 h after colorectal infusion of 100 lg PAR-4-AP or its vehicle, or 30 min after PAR-4 antagonist IP injection
in TNBS-induced hypersensitivity. Each line represents the mean EMG response of all animals tested in the same group. (A) 72 h after TNBS IC
infusion, EMG activity evoked by distension was increased at distension volumes from 0.02 to 0.06 mL, respectively demonstrating higher colo-
rectal sensitivity (TNBS, n = 12 vs saline, n = 10, *P < 0.05, **P < 0.01; ***P < 0.01). PAR-4-AP infusion reversed the effect (TNBS vs TNBS +
PAR-4-AP, n = 11, #P < 0.05, ###P < 0.001). (B) Interestingly, the PAR-4 antagonist (n = 9) augmented the hypersensitivity compared to TNBS
alone (TNBS vs TNBS + PAR-4-antagonist *P < 0.05, whereas saline vs TNBS, §P < 0.05). (C) Cat-G activity significantly increased in feces of
mice with TNBS colitis (n = 8, *P < 0.05) compared with naı¨ve controls (n = 8) or WAS-treated animals (n = 10). There was no difference
between naı¨ve controls and stressed animals (P > 0.05). D) MPO activity significantly increased in the colon of mice with TNBS colitis (n = 10,
P < 0.05) compared with naı¨ve controls (n = 10).
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previous data demonstrating that intraplantar injection
of PAR-4-AP was antinociceptive in the injected paw,
but not in the contralateral paw, showing a local
effect.9 In addition, TAP, a tight junction blocker used
for decades not only to block cation-selective perme-
ability in various epithelial tissues17,18 but also is
described as an inotropic agent which acts on potas-
sium conductance in epithelial cell levels, suppresses
the antinociceptive effect of PAR-4-AP. TAP activity is
preferentially mediated directly by its binding to sites
inside the tight junction cation channel.17 However,
there are no in vivo studies available comparing the
tight junction blocker properties of TAP and its ability
to act as an inotropic agent of potassium conductance
in epithelial cells. In addition, using TAP agent, a clear
link between epithelial intestinal permeability impair-
ment and visceral pain development was described in a
rat model of acute stress.19 This positive correlation is
now well established in IBS patients with hypersensi-
tivity, as high visceral pain criterion in these patients
is positively correlated with increased intestinal per-
meability.20,21 Therefore, taken together, these data
suggest that the responsible receptors explaining the
antinociceptive effect of PAR-4-AP are located beyond
the epithelial cell layer. Nevertheless, the PAR-4-AP
elicited increase in colonic permeability7 is not asso-
ciated with an increase, but a decrease of nociception,
still, the increase of permeability does not rule out the
antinociceptive effect.
The PAR-4 is expressed by Kupffer cells, B-lympho-
cytes,22 and mast cells,23 and its activation affects
leukocyte mobility.24,25 Our results show that colonic
lymphocytes do not play a role in the antinociceptive
effect of PAR-4-AP. Indeed, SCID mice were found
hyperalgesic to CRD26 and reconstitution of the mice
with CD4 + T cells restored visceral pain sensation
within the normal limits. The antinociceptive effect of
PAR-4-AP is still present in SCID mice suggesting that
such action does not require functional B or T cells.
However, the involvement of other immune cells, like
macrophages cannot be excluded with the use of SCID
mice, indeed, PAR-4 has been described on the mac-
rophages of rats.27 Incidentally, we have observed that
Balb/cBy mice are hyposensitive in our model of CRD
compared with C57BL/6J mice. Strain differences has
been described earlier in different experimental models
in terms of susceptibility to colitis28,29 or in antinoci-
ceptive responsiveness to N2O.
30 These data suggest
the presence of anatomic and/or functional differences
in the immune and neurologic system of these mice
strains, which may explain the observed dissimilarity
in their response to colorectal distension.
Induction of Fos expression is a marker of neuronal
activation, and CRD is a well-known stimulus to
activate primary visceral sensory afferents31 projecting
to the lumbosacral spinal cord in mice (L5-S1).32 CRD
induces Fos expression bilaterally in the L6-S2 spinal
segments particularly in laminae I and II located in the
dorsal horn. We observed a Fos protein overexpression
in mice after CRD in the L5-S1 segments of the spinal
cord. Parallel to the decreased sensitivity to CRD,
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Figure 4 Effect of Cat-G in water avoidance stress and TNBS-induced
colorectal hypersensitivity. Electromyographic activity of abdominal
muscle contractions evoked by CRD in mice 1 h after colorectal
infusion of 0.025 UN of Cat-G or its vehicle. (A) Cat-G restored the
basal EMG response in the WAS-induced visceral hypersensitivity
demonstrating an antihyperalgesic effect (saline vs WAS, *P < 0.05;
WAS vs WAS + Cat-G, #P < 0.05, ##P < 0.01). (B) In the TNBS model,
Cat-G could not influence the visceral hypersensitivity (saline vs
TNBS, *P < 0.05, **P < 0.01, ***P < 0.001; saline vs TNBS + Cat-G,
#P < 0.05, ##P < 0.01).
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Figure 5 Effect of PAR-4 activation on CRD-induced Fos expression in the spinal cord. (A) Fos immunostaining (arrowheads) of dorsal horn and
central area of the spinal cord (segment L5) in naive, undistended animals (n = 5), and after CRD in vehicle (n = 5) or PAR-4 AP-treated (n = 5) mice.
(B) Fos expression increased significantly in the lumbosacral spinal cord after CRD in the group treated with 0.9% saline (P < 0.001), whereas
PAR-4-AP decreased this CRD-induced Fos expression (P < 0.001).
Table 1 Low-grade inflammatory effect of 20 mg kg)1 TNBS in 30% ethanol intracolonically infused in C57BL/6J mice
Control mice
(day 0)
Control mice
(day 3)
TNBS mice before TNBS
instillation (day 0)
TNBS mice after TNBS
instillation (day 3)
Body weight (g) 22.7 ± 0.25 22.9 ± 0.35 23.3 ± 0.18 22.9 ± 0.22#
Colonic length (cm) – 7.93 ± 0.20 – 7.8 ± 0.08
Macroscopic damage
score (colonic mucosal
thickening)
– 0 ± 0 – 0.5 ± 0.02*
TNBS, 2,4,6-trinitrobenzene sulfonic acid.
Note only a slight colonic mucosal thickening compared with control and also a slight body weight loss of mice 3 days after TNBS instillation.
Mean ± SEM (n = 10). *P < 0.05 from control mice (day 3); #P < 0.05 from mice before TNBS instillation (day 0).
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PAR-4-AP attenuates Fos expression in the lumbosa-
cral spinal cord. This finding confirms that a decreased
neuronal activation is present behind the observed
hypoalgesia to CRD.
Endogenous antinociceptive role of PAR-4 in
inflammatory, but not non-inflammatory visceral
hyperalgesia
The PAR-1 and PAR-4 activation exert analgesic effect
to thermal and mechanical stimuli in a rat somatic
pain model in both basal and inflammatory condi-
tions.9,33 Further, PAR-4 activation has been shown to
reverse PAR-2 or TRPV-4 activation-induced colorectal
hypersensitivity in mice.14 Herein, we have extended
these observations to two visceral hypersensitivity
models. Stress is followed by the activation of colonic
mast cells34 responsible for a colonic barrier dysfunc-
tion.35 In contrast, in inflammatory hyperalgesia (coli-
tis) model, inflammatory mediators, such as
bradykinin can participate to the higher response to
colonic distension.36 Our results demonstrate that
despite the different origins of colorectal hyperalgesia,
PAR-4-AP exerts similar antihyperalgesic effects.
Surprisingly, in the TNBS colitis model the colo-
rectal hyperalgesia was augmented by blocking PAR-4
with an antagonist. This suggests the presence of an
endogenous activation of PAR-4 in colonic inflamma-
tion, exerting a feed-back antinociceptive effect,
which was not observed in the stress model. One
explanation may be that in TNBS colitis an invasion
of neutrophil granulocytes appears in the colonic
mucosa, acting as a source of inflammatory mediators,
such as Cat-G, a potent activator of PAR-437 that
reach sensitive nerve terminals and cause hyposensi-
tivity to CRD.6 In agreement with such hypothesis,
using a substrate not completely specific, but largely
used as one of the most specific substrate for Cat-G
activity evaluation,38,39 we found an increase of Cat-G
activity in the feces associated with neutrophil infil-
tration in mice with low-grade TNBS colitis, but not
in that of stressed mice. Taken together these data
may highlight a new role of Cat-G as an endogenous
PAR-4 agonist activating a feed-back loop to decrease
pain in inflammatory conditions. According to the
literature, we can also hypothesize that PAR-4 acti-
vated by Cat-G can exert this physiologic antinoci-
ceptive feedback loop similar to PAR-1 in
inflammatory condition via the release of endogenous
mediators like opioids. Indeed, PAR-1 activation
modulate paw inflammatory pain by triggering the
production of proenkephalin and the activation of
opioid receptors.40
Besides, the intracolonic administration of Cat-G
reversed the colorectal hypersensitivity in mice
evoked by WAS, but not by TNBS, whereas PAR-4-
AP was antihyperalgesic in both models. This finding
can be explained by the non-specificity of Cat-G on
PAR-4. Thus, Cat-G may disarm PAR-1 and PAR-2 on
human bronchial fibroblasts.41 Further, in cardiomyo-
cytes, Cat-G induces apoptosis via a PAR-independent
mechanism.37 On the other hand, inflammatory medi-
ators released in specific conditions may alter the
expression of PARs, which may affect PAR signaling
locally.41,42 Namely, TNF-a and LPS upregulates PAR-
2 and induces PAR-4 mRNA expression in human
bronchial fibroblasts.41 We may hypothesize that
similar changes appear in TNBS-induced colonic
inflammation, which alters the effects of Cat-G on
PARs due to its non-specificity. Indeed, in the WAS
model, where Cat-G release to the colonic wall is not
relevant, the endogenous PAR-4 activation is not
detectable, and extrinsic Cat-G exhibits an analgesic
effect by PAR-4 activation, similar to PAR-4-AP.
However, in the TNBS model, endogenous Cat-G is
already highly present in the colonic wall, and acti-
vates PAR-4 to exert an analgesic effect. Although
PAR-4-AP, a pure PAR-4 agonist is still antinocicep-
tive in this model, additional extrinsic Cat-G does not
reinforce the analgesic effect. This observation high-
lights the natural antinociceptive role of Cat-G in
endogenous concentrations in the TNBS model,
whereas increasing the concentration by external
administration brings the non-specific effects of
Cat-G to the front.
CONCLUSIONS
In summary, our results indicate that the antinocicep-
tive effects of PAR-4-AP are linked to a direct or
indirect activation of receptors located on colonic
nerve terminals, and that PAR-4-AP administration is
antinociceptive not only in basal, but also in stress and
inflammatory conditions. Endogenous activation of
PAR-4 plays an antinociceptive role in mild-TNBS
colitis, but not in stress-induced visceral hyperalgesia,
and Cat-G is a possible candidate to activate this
endogenous antinociceptive mechanism.
ACKNOWLEDGMENTS
Anita Annahazi is a recipient of a postdoctoral fellowship from
INRA. This work was supported by institutional grant from
INRA and TA´MOP (TA´MOP-4.2.2-08/01-2008-0002). The
authors thank Afifa Ait-Belgnaoui for her help in the method-
ology, and Mathilde Leveque and Patrice Rouby for their
technical assistance.
A. Annaha´zi et al. Neurogastroenterology and Motility
 2011 Blackwell Publishing Ltd84
AUTHOR CONTRIBUTION
AAperformed the research, analyzed the data andwrote the article.
MD, CSC, and AP performed the research and prepared the figures.
GK, AR, RR helped in the design of the study and the writing of the
article. VT, TW, LB designed the study. HE designed the study,
performed the research, analyzed the data and wrote the article.
COMPETING INTERESTS
None.
REFERENCES
1 Hollenberg MD, Compton SJ. Interna-
tionalUnionofPharmacology.XXVIII.
Proteinase-activated receptors. Phar-
macol Rev 2002; 54: 203–17.
2 Houle S, Papez MD, Ferazzini M,
Hollenberg MD, Vergnolle N. Neu-
trophils and the kallikrein-kinin sys-
tem in proteinase-activated receptor
4-mediated inflammation in rodents.
Br J Pharmacol 2005; 146: 670–8.
3 Kawabata A, Matsunami M, Sekigu-
chi F. Gastrointestinal roles for pro-
teinase-activated receptors in health
and disease. Br J Pharmacol 2008;
153(Suppl. 1): S230–40.
4 Coelho AM, Vergnolle N, Guiard B,
Fioramonti J, Bueno L. Proteinases
and proteinase-activated receptor 2: a
possible role to promote visceral
hyperalgesia in rats.Gastroenterology
2002; 122: 1035–47.
5 Gecse K, Roka R, Ferrier L et al.
Increased faecal serine protease
activity in diarrhoeic IBS patients:
a colonic lumenal factor impairing
colonic permeability and sensitivity.
Gut 2008; 57: 591–9.
6 Annahazi A, Gecse K, Dabek M et al.
Fecal proteases from diarrheic-IBS
and ulcerative colitis patients exert
opposite effect on visceral sensitivity
in mice. Pain 2009; 144: 209–17.
7 Dabek M, Ferrier L, Roka R et al.
Luminal cathepsin g and protease-
activated receptor 4. A Duet involved
in alterations of the colonic epithelial
barrier in ulcerative colitis.
Am J Pathol 2009; 175: 207–14.
8 Mule F, Pizzuti R, Capparelli A,
Vergnolle N. Evidence for the pres-
ence of functional protease activated
receptor 4 (PAR4) in the rat colon.
Gut 2004; 53: 229–34.
9 Asfaha S, Cenac N, Houle S et al.
Protease-activated receptor-4: a novel
mechanism of inflammatory pain
modulation. Br J Pharmacol 2007;
150: 176–85.
10 Shpacovitch V, Feld M, Bunnett NW,
Steinhoff M. Protease-activated
receptors: novel PARtners in innate
immunity. Trends Immunol 2007;
28: 541–50.
11 Bosma GC, Custer RP, Bosma MJ.
A severe combined immunodefi-
ciency mutation in the mouse. Nat-
ure 1983; 301: 527–30.
12 Larauche M, Gourcerol G, Million M,
Adelson DW, Tache Y. Repeated
psychological stress-induced altera-
tions of visceral sensitivity and
colonic motor functions in mice:
influence of surgery and postopera-
tive single housing on visceromotor
responses. Stress 2010; 13: 343–54.
13 Eutamene H, Bradesi S, Larauche M
et al. Guanylate cyclase C-mediated
antinociceptive effects of linaclotide
in rodent models of visceral pain.
Neurogastroenterol Motil 2010; 22:
e312–84.
14 Auge C, Balz-Hara D, Steinhoff M,
Vergnolle N, Cenac N. Protease-acti-
vated receptor-4 (PAR 4): a role as
inhibitor of visceral pain and hyper-
sensitivity. Neurogastroenterol Motil
2009; 21: 1189–e107.
15 Russell FA, Veldhoen VE, Tchitchkan
D, McDougall JJ. Proteinase-activated
receptor-4 (PAR4) activation leads to
sensitization of rat joint primary
afferents via a bradykinin B2 receptor-
dependent mechanism. J Neurophys-
iol 2010; 103: 155–63.
16 Karanjia R, Spreadbury I, Bautista-
Cruz F, Tsang ME, Vanner S. Activa-
tion of protease-activated receptor-4
inhibits the intrinsic excitability of
colonic dorsal root ganglia neurons.
Neurogastroenterol Motil 2009; 21:
1218–21.
17 Moreno JH. Blockage of gallbladder
tight junction cation-selective chan-
nels by 2,4,6-triaminopyrimidinium
(TAP). J Gen Physiol 1975; 66: 97–
115.
18 Moreno JH. Blockage of cation per-
meability across the tight junctions of
gallbladder and other leaky epithelia.
Nature 1974; 251: 150–1.
19 Ait-Belgnaoui A, Bradesi S, Fiora-
monti J, Theodorou V, Bueno L.
Acute stress-induced hypersensitivity
to colonic distension depends upon
increase in paracellular permeability:
role of myosin light chain kinase.
Pain 2005; 113: 141–7.
20 Piche T, Barbara G, Aubert P et al.
Impaired intestinal barrier integrity
in the colon of patients with irritable
bowel syndrome: involvement of sol-
uble mediators. Gut 2009; 58: 196–
201.
21 Zhou Q, Zhang B, Verne GN. Intes-
tinal membrane permeability and
hypersensitivity in the irritable bowel
syndrome. Pain 2009; 146: 41–6.
22 Rullier A, Senant N, Kisiel W et al.
Expression of protease-activated
receptors and tissue factor in human
liver. Virchows Arch 2006; 448:
46–51.
23 Moormann C, Artuc M, Pohl E et al.
Functional characterization and
expression analysis of the proteinase-
activated receptor-2 in human cuta-
neous mast cells. J Invest Dermatol
2006; 126: 746–55.
24 Cenac N, Coelho AM, Nguyen C
et al. Induction of intestinal inflam-
mation in mouse by activation of
proteinase-activated receptor-2. Am J
Pathol 2002; 161: 1903–15.
25 Moffatt JD, Lever R, Page CP. Effects
of inhaled thrombin receptor agonists
in mice. Br J Pharmacol 2004; 143:
269–75.
26 Verma-Gandhu M, Bercik P, Motom-
ura Y et al. CD4 + T-cell modulation
of visceral nociception in mice. Gas-
troenterology 2006; 130: 1721–8.
27 Jesmin S, Gando S, Zaedi S, Sakuraya
F. Differential expression, time
course and distribution of four PARs
in rats with endotoxin-induced acute
lung injury. Inflammation 2007; 30:
14–27.
28 Scheiffele F, Fuss IJ. Induction of
TNBS colitis in mice. Curr Protoc
Immunol 2002; 15.19: 1–15.
29 Melgar S, Hammarstrom S, Oberg A,
Danielsson A, Hammarstrom ML.
Cytolytic capabilities of lamina pro-
pria and intraepithelial lymphocytes
in normal and chronically inflamed
human intestine. Scand J Immunol
2004; 60: 167–77.
Volume 24, Number 1, January 2012 PAR4 activation in visceral inflammatory pain
 2011 Blackwell Publishing Ltd 85
30 Quock RM, Mueller JL, Vaughn LK.
Strain-dependent differences in
responsiveness of mice to nitrous
oxide (N2O) antinociception. Brain
Res 1993; 614: 52–6.
31 Traub RJ, Herdegen T, Gebhart GF.
Differential expression of c-fos and
c-jun in two regions of the rat spinal
cord following noxious colorectal dis-
tention.NeurosciLett1993;160:121–5.
32 Christianson JA, Traub RJ, Davis BM.
Differences in spinal distribution and
neurochemical phenotype of colonic
afferents in mouse and rat. J Comp
Neurol 2006; 494: 246–59.
33 Asfaha S, Brussee V, Chapman K,
Zochodne DW, Vergnolle N. Protein-
ase-activated receptor-1 agonists
attenuate nociception in response to
noxious stimuli. Br J Pharmacol
2002; 135: 1101–6.
34 Gue M, Del Rio-Lacheze C, Eutam-
ene H, Theodorou V, Fioramonti J,
Bueno L. Stress-induced visceral
hypersensitivity to rectal distension
in rats: role of CRF and mast cells.
Neurogastroenterol Motil 1997; 9:
271–9.
35 Santos J, Yang PC, Soderholm JD,
Benjamin M, Perdue MH. Role of
mast cells in chronic stress induced
colonic epithelial barrier dysfunction
in the rat. Gut 2001; 48: 630–6.
36 Couture R, Harrisson M, Vianna RM,
Cloutier F. Kinin receptors in pain
and inflammation. Eur J Pharmacol
2001; 429: 161–76.
37 Sabri A, Alcott SG, Elouardighi H
et al. Neutrophil cathepsin G
promotes detachment-induced car-
diomyocyte apoptosis via a protease-
activated receptor-independent
mechanism. J Biol Chem 2003; 278:
23944–54.
38 Raymond WW, Trivedi NN, Makar-
ova A et al. How immune peptidases
change specificity: cathepsin G
gained tryptic function but lost effi-
ciency during primate evolution.
J Immunol 2010; 185: 5360–8.
39 Liao CH, Chen JJ, Lin JE et al. 5-
hydroxy-2-(4-hydroxy-3-methoxyphe-
nyl)-3,7-dimethoxy-4H-chromen-4-one
(MSF-2) suppresses fMLP-mediated
respiratory burst in human neu-
trophils by inhibiting phosphatidyl-
inositol 3-kinase activity. J Cell
Physiol 2011; 226: 1519–30.
40 Martin L, Auge´ C, Boue´ J et al.
Thrombin receptor: an endogenous
inhibitor of inflammatory pain, acti-
vating opioid pathways. Pain 2009;
146: 121–9.
41 Ramachandran R, Sadofsky LR, Xiao
Y et al. Inflammatory mediators
modulate thrombin and cathepsin-G
signaling in human bronchial fibro-
blasts by inducing expression of pro-
teinase-activated receptor-4. Am J
Physiol 2007; 292: L788–98.
42 D’Andrea MR, Saban MR, Nguyen
NB, Andrade-Gordon P, Saban R.
Expression of protease-activated
receptor-1, -2, -3, and -4 in control and
experimentally inflamed mouse
bladder. Am J Pathol 2003; 162: 907–
23.
A. Annaha´zi et al. Neurogastroenterology and Motility
 2011 Blackwell Publishing Ltde13
